Day: January 24, 2026

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...

CAPNOS LEGURA Vape Replacement Investigated: 2026 Consumer Analysis Examines Nicotine-Free Behavioral Aid Technology and Safety Documentation

Independent evaluation explores patent-pending pressurized air throat hit technology, no-heat no-vapor valve mechanism, third-party material safety testing, and oral fixation...

error: Content is protected !!